Your browser doesn't support javascript.
loading
NCAPG2 promotes prostate cancer malignancy and stemness via STAT3/c-MYC signaling.
Zhang, Enchong; Chen, Zhengjie; Liu, Wangmin; Lin, Lin; Wu, Lina; Guan, Johnny; Wang, Jianfeng; Kong, Chuize; Bi, Jianbin; Zhang, Mo.
Afiliação
  • Zhang E; Department of Urology, Shenjing Hospital of China Medical University, Shenyang, China.
  • Chen Z; Department of Urology, The First Hospital of China Medical University, Shenyang, China.
  • Liu W; Institute of Urology, China Medical University, Shenyang, China.
  • Lin L; Department of Urology, Shenjing Hospital of China Medical University, Shenyang, China.
  • Wu L; Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA.
  • Guan J; Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, China.
  • Wang J; Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA.
  • Kong C; Department of Urology, The First Hospital of China Medical University, Shenyang, China.
  • Bi J; Institute of Urology, China Medical University, Shenyang, China.
  • Zhang M; Department of Urology, The First Hospital of China Medical University, Shenyang, China.
J Transl Med ; 22(1): 12, 2024 01 02.
Article em En | MEDLINE | ID: mdl-38166947
ABSTRACT

BACKGROUND:

Prostate cancer (PCa) is the second leading cause of cancer-related mortality among men worldwide, and its incidence has risen substantially in recent years. Therefore, there is an urgent need to identify novel biomarkers and precise therapeutic targets for managing PCa progression and recurrence.

METHODS:

We investigated the clinical significance of NCAPG2 in PCa by exploring public datasets and our tissue microarray. Receiver operating characteristic (ROC) curve and survival analyses were performed to evaluate the correlation between NCAPG2 and PCa progression. Cell proliferation, wound healing, transwell, flow cytometry, cell cycle, tumor sphere formation, immunofluorescence (IF), co-immunoprecipitation (co-IP), and chromatin immunoprecipitation (ChIP) assays were conducted to further elucidate the molecular mechanism of NCAPG2 in PCa. Subcutaneous and orthotopic xenograft models were applied to investigate the effects of NCAPG2 on PCa proliferation in vivo. Tandem mass tag (TMT) quantitative proteomics was utilized to detect proteomic changes under NCAPG2 overexpression.

RESULTS:

NCAPG2 was significantly upregulated in PCa, and its overexpression was associated with PCa progression and unfavorable prognosis. Knockdown of NCAPG2 inhibited the malignant behavior of PCa cells, whereas its overexpression promoted PCa aggressiveness. NCAPG2 depletion attenuated the development and growth of PCa in vivo. TMT quantitative proteomics analyses indicated that c-MYC activity was strongly correlated with NCAPG2 expression. The malignancy-promoting effect of NCAPG2 in PCa was mediated via c-MYC. NCAPG2 could directly bind to STAT3 and induce STAT3 occupancy on the MYC promoter, thus to transcriptionally activate c-MYC expression. Finally, we identified that NCAPG2 was positively correlated with cancer stem cell (CSC) markers and enhanced self-renewal capacity of PCa cells.

CONCLUSIONS:

NCAPG2 is highly expressed in PCa, and its level is significantly associated with PCa prognosis. NCAPG2 promotes PCa malignancy and drives cancer stemness via the STAT3/c-MYC signaling axis, highlighting its potential as a therapeutic target for PCa.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Proteínas Cromossômicas não Histona / Proteínas Proto-Oncogênicas c-myc Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: J Transl Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Proteínas Cromossômicas não Histona / Proteínas Proto-Oncogênicas c-myc Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: J Transl Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China